The clinical comparative study on hydroxycomptothecin combined with cocurrent hyperfractionated radiotherapy for unresectable stage III non-small cell lung cancer / 肿瘤

ABSTRACT

Objective: To investigate the efficacy, toxicity and long-term outcome of hydroxycomptothecin (HCPT) combined concurrent hyperfractionated radiotherapy for unresectable stage III non-small cell lung cancer (NSCLC). Methods: Sixty patients were enrolled into this study and divied into experimental group (n = 30) and control group (n = 30). The patients in the experimental group were administered HCPT at 10 mg/d in NS 250 mL (iv, daily) on the first 5 days and the last 5 days during radiotherapy. The patients were given concurrent hyperfractionated radiotherapy at 1.2 Gy, twice daily. The total dosage of radiation was 62.4-67.2 Gy. Patients in the control group only received hyperfractionated radiotherapy. The long-term survival rate was estimated by Kaplan-Meier survival curve. Results: Fifty-eight patients finished the trial. The follow-up rate was 96%. The response rate was 80% in the experimental group and 66.7% in the control group, respectively (P > 0.05). There was no significant difference in hematologic and non hematologic toxicities between the two groups (P > 0.05). The predicted 1- and 3-year survival rates were 77.7% and 26.1% for the experimental group and 70.3% and 15.1% for the control group, respectively. There was no significant difference between two groups (P > 0.05). Conclusion: HCPT combined concurrent hyperfractionated radiotherapy has definite effects on unresectable stage III NSCLC. The efficacy of combined therapy is better than hyperfractionated radiotherapy, and but the difference was not significant. The toxicity could be torerated.